Investigating the in vivo bioequivalence of Apprepitant 125 mg capsule
Not Applicable
- Conditions
- In the present study, the products will be administered to healthy volunteers..
- Registration Number
- IRCT20210519051345N14
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years old)
Exclusion Criteria
Smoking,
History of cardiovascular disease, liver and kidney disease,
Pregnancy,
Alcohol and drug addiction,
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: 0.5-72 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method